113
Participants
Start Date
June 17, 2021
Primary Completion Date
January 27, 2023
Study Completion Date
April 28, 2023
OC-01 (varenicline) nasal spray 1.2 mg/ml
OC-01
Placebo (vehicle) nasal spray
Placebo (vehicle)
New York NY, New York
Babylon New York, Babylon
York, Pennsylvania, York
Bowie, Maryland, Bowie
Lynchburg Virginia, Lynchburg
Atlanta, Georgia, Atlanta
Jacksonville Florida, Jacksonville
Miami Florida, Miami
Brandon Florida, Brandon
Brandon, Florida, Brandon
Dothan Alabama, Dothan
Louisville KY, Louisville
Union Kentucky, Edgewood
Hoffman Estates, Illinois, Hoffman Estates
Urbana Illinois, Urbana
Kansas City Missouri, Kansas City
Houston Texas, Houston
Katy, Texas, Katy
San Antonio Texas, San Antonio
Aurora Colorado, Aurora
Littleton, Colorado, Littleton
Longmont, Colorado, Longmont
Henderson Nevada, Henderson
Los Angeles California, Los Angeles
Mission Hills California, Mission Hills
Irvine, California, Irvine
Seattle Washington, Seattle
Danbury, Connecticut, Danbury
Boston Massachusetts, Boston
Bloomfield, New Jersey, Bloomfield
Dover New Jersey, Dover
Lead Sponsor
Oyster Point Pharma, Inc.
INDUSTRY